"Ganciclovir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
| Descriptor ID |
D015774
|
| MeSH Number(s) |
D03.633.100.759.758.399.454.250.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ganciclovir".
Below are MeSH descriptors whose meaning is more specific than "Ganciclovir".
This graph shows the total number of publications written about "Ganciclovir" by people in this website by year, and whether "Ganciclovir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 2 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 1 | 5 | 6 |
| 2001 | 2 | 2 | 4 |
| 2002 | 0 | 3 | 3 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 3 | 4 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 1 | 3 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ganciclovir" by people in Profiles.
-
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2025 01 14; 1:CD005133.
-
Cytomegalovirus urinary excretion in children with congenital and postnatally acquired infection. J Clin Virol. 2025 Feb; 176:105756.
-
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2024 05 03; 5:CD003774.
-
Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial. J Pediatr. 2024 05; 268:113934.
-
Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients. Am J Transplant. 2023 12; 23(12):1961-1971.
-
Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy. J Pediatric Infect Dis Soc. 2022 Jan 27; 11(1):16-23.
-
Multiplexed drug-based selection and counterselection genetic manipulations in Drosophila. Cell Rep. 2021 09 14; 36(11):109700.
-
Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. Am J Transplant. 2022 01; 22(1):187-198.
-
Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells. Neurosurgery. 2016 Sep; 79(3):481-91.
-
Panresistant cytomegalovirus in a kidney transplant recipient. Pharmacotherapy. 2014 Jan; 34(1):e1-3.